For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaceutical development company Pharmaxis today announced that it has completed preclinical development of its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) and is ready to commence human clinical phase I studies in Q1 2015.
The SSAO/VAP-1 enzyme contributes to various forms of chronic inflammation in humans and is a marker for disease severity in conditions such as atherosclerosis, liver and kidney inflammation. Pharmaxis will focus the clinical development on inflammatory diseases with high unmet clinical need including Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Steatohepatitis (NASH).Read full media release - pdf
Pharmaxis today announced that on 1 August 2014 (US time) it filed a lawsuit against NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest") in response to an attempt by NovaQuest to back out of its funding obligations under the Financing Agreement signed in January 2013 between Pharmaxis and NovaQuest.Read full media release - pdf